The top gastroenterology biosimilar news from 2024 highlight fluctuations in the adalimumab biosimilar market throughout the ...
Number 3: Sandoz's biosimilar denosumab (Jubbonti/Wyost) has demonstrated analytical, pharmacokinetic, pharmacodynamic, and clinical equivalence to reference denosumab (Prolia/Xgeva), supporting its ...
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf ...
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf ...
China's trastuzumab biosimilar market is growing but lags behind European countries, with biosimilars gradually increasing ...
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf ...
A systematic review identified 13 strategies, including patient and provider education, empathetic communication, and shared ...
The FDA approved Celltrion's Steqeyma (ustekinumab-stba), making it the seventh biosimilar slated to compete against blockbuster Stelara (reference ustekinumab) in 2025. The FDA has approved Steqeyma ...
A recent study showed similar safety and efficacy of a bevacizumab biosimilar compared with the reference product (Avastin) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback